Pharma BD Deal Intelligence
A bust: Sanofi's $1.7B licensing deal for sotagliflozin fell apart when it terminated the agreement in 2019 after regulatory setbacks, leaving Lexicon to independently win approval for the drug (as Inpefa) for heart failure in 2023.
Under the terms of the agreement, Lexicon will receive an upfront payment of $300 million and is eligible to receive development, regulatory and sales…
Lexicon fires back after Sanofi ends up-to-$1.7B diabetes collaboration. Total deal potential was $1.7 billion including $300 million upfront and $1.4 billion…
Sanofi partners with Lexicon Pharmaceuticals to develop sotagliflozin, with Lexicon receiving a $300 million upfront payment and eligibility for up to…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Sanofi licensed sotagliflozin, a dual SGLT1/SGLT2 inhibitor, from Lexicon for global development and commercialization in diabetes and cardiovascular disease. Lexicon received $300M upfront, $100M equity, with up to $2.42B in milestones. The deal was terminated by Sanofi in 2019 following regulatory setbacks. Lexicon later independently obtained approval for Inpefa (sotagliflozin) for heart failure in 2023.
550K US cases/yr · $11.0B Global Heart Failure Market (2017) · 33% CV Death/HF Reduction (SOLOIST-WHF)
Sotagliflozin inhibits both SGLT1 (gut) and SGLT2 (kidney), providing complementary cardiorenal protection. SOLOIST-WHF demonstrated 33% reduction in CV death and HF events.
Sotagliflozin (Inpefa, Lexicon) competes with selective SGLT2 inhibitors dapagliflozin (Farxiga, AstraZeneca; DAPA-HF, DELIVER) and empagliflozin (Jardiance, Lilly/Boehringer Ingelheim; EMPEROR-Reduced, EMPEROR-Preserved) which both hold broad HFrEF and HFpEF labels. Adjacent HF backbone includes sacubitril/valsartan (Entresto, Novartis) and finerenone (Kerendia, Bayer).
550K US cases/yr · $11.0B Global Heart Failure Market (2017) · ~50% 5-Year HF Mortality Rate
Sotagliflozin's dual SGLT1/SGLT2 inhibition offered broader cardiorenal benefits than SGLT2-only inhibitors, with additional gut-level glucose absorption reduction.
Inpefa (sotagliflozin, Lexicon) competes in HF with SGLT2 inhibitors dapagliflozin (Farxiga, AstraZeneca) and empagliflozin (Jardiance, Lilly/Boehringer Ingelheim), both with broad HFrEF/HFpEF labels. Background standards include sacubitril/valsartan (Entresto, Novartis), beta blockers, MRAs (spironolactone, Kerendia/finerenone), and loop diuretics.
64K US cases/yr · $8.0B Global T1D Market (2017) · ~33% T1D Patients at HbA1c Goal
Sotagliflozin was investigated as an oral adjunct to insulin for T1D. The dual SGLT1/2 mechanism delays gut glucose absorption while promoting renal excretion. DKA risk proved a significant hurdle.
EU CHMP rejected sotagliflozin for T1D in 2019 due to DKA concerns, triggering Sanofi's exit. The T1D indication was abandoned.
Sanofi licensed sotagliflozin, a dual SGLT1/SGLT2 inhibitor, from Lexicon for global development and commercialization in diabetes and cardiovascular disease. Lexicon received $300M upfront, $100M equity, with up to $2.42B in milestones. The deal was terminated by Sanofi in 2019
Transaction terminated. tones. The deal was terminated by Sanofi in 2019 following regulatory setbacks. Lexicon later independently obtained approval for Inpefa (sotagliflozin) for heart failure
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Lexicon Pharmaceuticals Inc. (this deal) | 2015 | $1.7B | 44 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2015 deals · Sanofi SA deals · Cardiovascular deals